A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
NCT06563895 · RECRUITING · Phase 3
We track 1 ClinicalTrials.gov studies led by Eidos Therapeutics A Bridgebio Company. The portfolio skews toward Phase 3 (1 trials).
1 clinical trials sponsored by Eidos Therapeutics A Bridgebio Company.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 3 | 1 | 100% |
Eidos Therapeutics A Bridgebio Company currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 3.
Eidos Therapeutics A Bridgebio Company conducts research across multiple therapeutic areas. Browse the trial listings for details.
Yes, Eidos Therapeutics A Bridgebio Company currently has 1 trial that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.